SCHEMBL9976045

SCHEMBL9976045

CCOC(=O)C(=O)NCc1ccc(Cl)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
GAA P10253 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
TP53 P04637 1/20 0.56
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
EPHX2 P34913 2/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
HPGD P15428 2/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
MAPT P10636 1/20 0.52
LMNA P02545 1/20 0.52
THRB P10828 1/20 0.51
TSHR P16473 1/20 0.50
PLAAT3 P53816 1/20 0.49
PLAAT5 Q96KN8 1/20 0.49
PLAAT2 Q9NWW9 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12143938 0.87 SMN1; SMN2 (0.57) ALDH1A1SMN1; SMN2GAATP53MEN1
SCHEMBL11068784 0.85 MEN1 (0.61) ALDH1A1SMN1; SMN2TP53MEN1KMT2A
SCHEMBL10047770 0.84 CYP2C9 (0.51) ALDH1A1SMN1; SMN2GAATDP1TP53
SCHEMBL13860776 0.84 MAPT (0.62) GAATDP1TP53MEN1KMT2A
SCHEMBL15682691 0.84 MEN1 (0.53) ALDH1A1GAATDP1MEN1KMT2A
SCHEMBL6333483 0.83 SMN1; SMN2 (0.69) ALDH1A1SMN1; SMN2GAAMEN1KMT2A
SCHEMBL11169677 0.83 PPID (0.60) ALDH1A1SMN1; SMN2GAAMEN1KMT2A
SCHEMBL20681282 0.83 TSHR (0.57) ALDH1A1SMN1; SMN2GAATDP1MEN1
SCHEMBL30965434 0.83 TSHR (0.57) ALDH1A1SMN1; SMN2GAATDP1MEN1
SCHEMBL12145481 0.83 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2TP53MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546397-B2 DNA methylation inhibitors THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2013-10-01 US disclosed
US-8546397-B2 DNA methylation inhibitors THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2013-10-01 US disclosed
WO-2012087889-A2 DNA METHYLATION INHIBITORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2012-06-28 WO disclosed
US-20120157465-A1 DNA METHYLATION INHIBITORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2012-06-21 US disclosed
US-20120157465-A1 DNA METHYLATION INHIBITORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157465-A1 DNA METHYLATION INHIBITORS MECP2, DNMT1, DNMT3B ALDH1A1 2789/4885SMN1; SMN2 3853/4885GAA 3947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.